Corteva, Inc. Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026, for Corteva, Inc. (CTVA) and its subsidiary EIDP, Inc. Corteva operates in two segments: Seed and Crop Protection. The company is currently preparing for a proposed separation into two independent publicly traded companies, one for each segment, announced in October 2025. The filing includes a combined report for both Corteva and EIDP, with EIDP filing under reduced disclosure format as a wholly-owned subsidiary.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $4,905 | $4,417 |
| Net Income (Attributable to Corteva) | $720 | $652 |
| Diluted EPS | $1.07 | $0.95 |
| Operating EBITDA (Non-GAAP) | $1,438 | $1,189 |
| Free Cash Flow (Non-GAAP) | $(2,966) | $(2,195) |
| Cash and Cash Equivalents | $1,964 | $2,008 |
| Total Debt | $3,356 | $4,083 |
Note: Free Cash Flow calculated as Operating Cash Flow from continuing operations ($2,885M outflow) less Capital Expenditures ($81M).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% year-over-year, driven by a 6% volume increase, 4% favorable currency impact, and 1% price increase. Seed sales rose 12% to $3.02 billion, while Crop Protection sales rose 10% to $1.88 billion.
- Profitability: Net income increased 10% to $720 million. Operating EBITDA margin improved, with Seed segment EBITDA up 23% and Crop Protection EBITDA up 15%.
- Restructuring Charges: Restructuring and asset-related charges increased significantly to $92 million (from $22 million in Q1 2025). This includes $78 million in severance costs related to the "2026 Restructuring Actions" to align the organization for the proposed separation.
- Other Income/Expense: Other income (expense) swung from a $15 million gain in Q1 2025 to a $117 million loss in Q1 2026. This was primarily due to a $610 million settlement payment to Bayer (of which ~$546 million was paid in Q1 2026) and net exchange losses.
- Cash Flow: Operating cash flow from continuing operations was a use of $2.89 billion, compared to $2.11 billion in the prior year. The increase in outflow was driven by the Bayer settlement payment, higher compensation payments, and lower customer prepayments.
Guidance, Outlook, and Risks
- Proposed Separation: The company intends to separate its Seed and Crop Protection businesses into two independent companies. Management expects the separation to be tax-free for U.S. federal income tax purposes. A $1.5 billion contribution to the principal U.S. pension plan was approved in April 2026 to be made by July 31, 2026.
- Restructuring Outlook: The 2026 Restructuring Actions are expected to be substantially complete by December 2026, with total pre-tax charges estimated at $70–$80 million. These actions are projected to generate $115–$125 million in run-rate savings by 2027.
- Capital Allocation: The company returned approximately $370 million to shareholders in Q1 2026 via dividends ($121 million) and share repurchases ($250 million). For the first half of 2026, the company expects repurchases of approximately $500 million under its 2024 Share Buyback Plan.
- Legal and Environmental Risks:
- Bayer Dispute: Resolved in Q1 2026 with a $610 million settlement, terminating litigation and future royalty obligations on Enlist E3 soybeans.
- FTC Investigation: A trial regarding antitrust claims is expected to begin in 2027. Tentative settlements were reached with the State of Arkansas and multi-district litigation plaintiffs in early 2026.
- PFAS Litigation: Ongoing exposure related to legacy EIDP businesses. A $1.185 billion settlement was finalized in April 2024 for nationwide water district claims. A New Jersey statewide settlement of $875 million (net present value ~$500 million) is pending court approval.
Key Facts for Investor Verification
- Bayer Settlement Impact: Verify the full cash outflow timing and the long-term strategic benefit of terminating royalty obligations on Enlist E3 soybeans.
- Separation Timeline: Monitor progress on regulatory approvals and the finalization of the separation plan for the Seed and Crop Protection businesses.
- Working Capital Seasonality: Note the significant cash outflow in Q1 due to seasonal working capital needs and the Bayer payment; assess if this is a recurring pattern or a one-time anomaly.
- PFAS Liability Exposure: Review the status of the New Jersey settlement approval and the potential for additional state-level settlements that could trigger supplemental payments under the Delaware settlement agreement.
- Argentina Exposure: Confirm the impact of the Argentine Peso devaluation on net monetary assets and the effectiveness of the company's hedging and bond-holding strategy.